After a long silence, GTx speaks.
This article is based on information obtained from the recorded replay of the Bio CEO and Investor Conference held on Feb 10. Aside from it, GTx has been in a silent period since a brief earnings call held Nov 12, 2013. The company has presented clinical data at several well-respected academic meetings in 2012 and 2013, including the Oct 24 15th Annual Lung Cancer Conference; the Dec 12 San Antonio Breast Cancer Symposium; and the Jan 14 ASCO Genitourinary Cancer Conference. However, no direct company information has been released since the Nov 12 call. At that point there had been no announced contact with the regulators, the FDA and EMEA. This...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|